SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Four proteins (Scavenger receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a previously established association with incident diabetes and 3 proteins (Cathepsin D, Galectin-4, Paraoxonase type 3) with a novel association with incident diabetes.
|
30670722 |
2019 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
However, inflammatory biomarkers hs-CRP [hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p=0.005], procalcitonin [HR 1.34, (95% CI 1.07 to 1.69), p=0.012] and PAI-1 [HR 1.55, (95% CI 1.37 to 1.75), p<0.001] remained significantly associated with new-onset DM, even after multivariable adjustment for established predictors of DM.
|
29074040 |
2018 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
We recently revealed that plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor, is involved in diabetes, osteoporosis and muscle wasting induced by glucocorticoid (GC) treatment in mice.
|
28321652 |
2018 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 deficiency did not affect the mRNA levels of iNOS and IL-6 in F4/80- and CD11b-double-positive cells from the bone marrow of the damaged femurs decreased by diabetes in mice.
|
29534207 |
2018 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Compared to PBS treatment, APX3330 treatment significantly decreases plasminogen activator inhibitor type-1 (PAI-1), monocyte chemotactic protein-1 and matrix metalloproteinase 9 (MMP9) and receptor for advanced glycation endproducts expression in the ischemic brain of T1DM stroke rats.
|
29896433 |
2018 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
This study investigated PAI-1 serum level and MMP-3 activity and their correlation with glomerular filtration rate in patients with diabetes mellitus.
|
29421776 |
2018 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
The aim was to evaluate tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) concentration using enzyme linked immunosorbent assay method (ELISA) in diabetic foot syndrome (DFS) as compared to a group of healthy people and patients with diabetes mellitus without symptomatic vascular complications (DM2T).
|
28193577 |
2017 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that a PAI-1 specific inhibitor alleviated diabetes-induced delays in skin and muscle repair.
|
29311999 |
2017 |
SERPINE1
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1.
|
28771557 |
2017 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
From our longitudinal cohort study, we selectively recruited chronically stable HIV-infected individuals without diagnosis of diabetes mellitus at baseline (N = 62) to analyze the correlation of baseline inflammatory cytokines, including PAI-1 and whole-body insulin sensitivity, with 2-year follow-up, as measured by Matsuda Index.
|
28322572 |
2017 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 activity was increased in hyperlipidemic compared to healthy dogs, but there was no significant difference between dogs with hyperadrenocorticism and diabetes mellitus.
|
28266313 |
2017 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
(1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p < 0.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively.
|
26616527 |
2016 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Compared with 55 (33.3%) individuals in whom OSAS was not confirmed, OSAS patients had prolonged CLT (+12.8%), associated with higher PAI-1 antigen (+18.1%) (after adjustment for age, diabetes, and body mass index; both P < 0.01) and similar levels of TAFIa, plasmin, or antiplasmin.
|
27167858 |
2016 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice.
|
25552599 |
2015 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
To address this, we used type 1 diabetes mouse model induced by streptozocin to be hyperglycemic for 8 weeks, and isolated endothelial cells that were used either freshly after isolation or after 2 to 3-week cell culture in normoglycemic conditions. mRNA expression profiling in diabetic mouse endothelial cells revealed significant and persistent up-regulation of Serpine1 encoding PAI-1, the hypo-fibrinolytic mediator leading to thrombotic diseases in diabetes, along with Rock2, Fn1 and Ccl2, whereas only Serpine 1 was persistently elevated in high glucose-treated mouse endothelial cells.
|
23454124 |
2013 |
SERPINE1
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated.
|
24223897 |
2013 |
SERPINE1
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM.
|
21519150 |
2011 |
SERPINE1
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
|
21070757 |
2011 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Increased levels of PAI-1 and glycated low-density lipoprotein (glyLDL) were detected in patients with diabetes.
|
20630999 |
2010 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Since TGF-beta1 is well known to stimulate the PAI-1 promoter, we suggest that TGF-beta1 and PAI-1 together constitute a positive feedback loop in the development of renal fibrosis in diabetes.
|
19786738 |
2009 |
SERPINE1
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome.
|
18160587 |
2008 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1), produced partly from liver is a risk factor for macrovascular and microvascular complications of diabetes.
|
18700166 |
2008 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Patients most likely to benefit from PAI-1 inhibition would be those at high risk for vascular events where PAI-1 is elevated, such as is observed in obesity, diabetes and the metabolic syndrome.
|
17896948 |
2007 |
SERPINE1
|
0.300 |
Biomarker
|
group |
BEFREE |
Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase in cardiomyocytes and induction of TGF-beta and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells.
|
16339923 |
2006 |